Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Investor Presentation (April 2024)
14 slides from Abcellera Biologics's investor presentation, April 2024
Slide 1: Corporate Overview
CORPORATE OVERVIEW CO PYRIG HT © ABCELLERA April 2024
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements These statements involve risks, uncertainties and other factors that may CORPORATE OVERVIEW made pursuant to the safe harbor provisions of the Private Securities cause actual results, levels of activity, performan
Slide 3: Most important drivers of productivity in drug development
The most important drivers of productivity in drug development are: CORPORATE OVERVIEW New insights into Novel solutions to the biology of disease challenging problems COPYRIGHT © ABCELLERA 3
Slide 4: We have built an engine to generate first-in-class and best-in-class antibody medicines
We have built an engine to generate first-in-class and best-in-class antibody medicines. CORPORATE OVERVIEW Build a competitive advantage Investments in technological capability can improve the productivity of drug development. So you can solve hard problems COPYRIGHT © ABCELLERA Long-term value cre
Slide 5: After more than a decade, we are in the final stages of completing the engine
After more than a decade, we are in the final stages of completing the engine. CORPORATE OVERVIEW • 11+ years of investment in technology, teams, and infrastructure Manufacturing On Line Late 2025 • More than $500M in platform investments, with integration from target to the clinic • Final capital e
Slide 6: Our Partner Portfolio
O UR PA RT NE R PO RT FO LI O 90% human health: target antigen known n = 78 We built industry- 9% leading capabilities animal through partnerships health CORPORATE OVERVIEW n=8 with the top-tier of biotech and pharma 18% neurology 12% partners. immunology 1% human health: target antigen • Validated
Slide 7: Our Partners
O UR PA RT NE R S We are increasingly Expanding relationships focused on strategic with large pharma and large biotech partnerships. CORPORATE OVERVIEW We look for partnerships that bring new T-cell engager platform insights into novel biology or access to deals in oncology and autoimmune conditions
Slide 8: We are evolving into an integrated clinical biotech
OUR FUTURE $1B in availability liquidity to execute on our strategy We are evolving $780M in total cash, cash equivalents, & into an integrated CORPORATE OVERVIEW marketable securities clinical biotech. $220M in non-dilutive funding to execute on strategy We have the platform and capital to build a
Slide 9: We are unlocking high-value drug targets
OUR ENGINE. P LATFOR M DEVELOP MENT We are unlocking 100% human health n = 19 high-value drug targets. CORPORATE OVERVIEW GPCR & Ion Channel Platform • Clinically validated, membrane-protein targets with large commercial potential that have proven largely intractable 53% 42% using traditional method
Slide 10: We are advancing an internal pipeline
OUR PIPELINE We are advancing an internal • First two IND submissions anticipated in 2025 pipeline of potential first-in- • We intend to take additional first-in-class development candidates into IND-enabling class and best-in-class assets studies in 2024 and 2025 • $220M in non-dilutive funding fro
Slide 11: Our Pipeline: ABCL635
OUR PIPELINE. ABCL635 A potential Molecule ABCL635 first-in-class Status Target IND-enabling studies (Preclinical) Undisclosed - GPCR or ion channel antibody therapy CORPORATE OVERVIEW MOA Antagonist for metabolic and Indication Undisclosed endocrine conditions. Therapeutic Area Metabolic & endocrin
Slide 12: Our Pipeline: ABCL575
OUR PIPELINE. ABCL575 Molecule ABCL575 ABCL575 is Status IND-enabling studies (Preclinical) a potential Target MOA OX40 ligand (OX40L) Blocking and non-depleting best-in-class and • Atopic dermatitis (AD) CORPORATE OVERVIEW Indication second-in-class • Other indications in autoimmunity and inflammat
Slide 13: Summary
SUMMMARY Completion of Engine Over the next 2 years we will continue to invest in the final Continued focus stage of our engine, including construction and commissioning of our manufacturing facility: capital on high-value expenditures will be similar to last year. Our capital allocation is shifting
Slide 14: Thank You
COPYRIGHT © ABCELLERA 14 CORPORATE OVERVIEW YOU THANK
AbCellera Biologics — Investor Presentation (April 2024) on 6ix